Diagnostics and Therapeutics for Diseases Associated With G-Protein-Coupled Receptor Gpr39 (Gpr39)
The invention provides a human GPR39 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR39 as well as pharmaceutical compositions comprising such compounds.
1 . A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases in a mammal comprising the steps of
i) contacting a test compound with a GPR39 polypeptide, and
ii) detect binding of said test compound to said GPR39 polypeptide.
2 . A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases in a mammal comprising the steps of
i) determining the activity of a GPR39 polypeptide at a certain concentration of a test compound or in the absence of said test compound, and
ii) determining the activity of said polypeptide at a different concentration of said test compound.
3 . A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases in a mammal comprising the steps of
i) determining the activity of a GPR39 polypeptide at a certain concentration of a test compound, and
ii) determining the activity of a GPR39 polypeptide at the presence of a compound known to be a regulator of a GPR39 polypeptide.
4 . The method of claim 1 , wherein the step of contacting is in or at the surface of a cell.
5 . The method of claim 1 , wherein the cell is in vitro.
6 . The method of claim 1 , wherein the step of contacting is in a cell-free system.
7 . The method of claim 1 , wherein the polypeptide is coupled to a detectable label.
8 . The method of claim 1 , wherein the compound is coupled to a detectable label.
9 . The method of claim 1 , wherein the test compound displaces a ligand which is first bound to the polypeptide.
10 . The method of claim 1 , wherein the polypeptide is attached to a solid support.
11 . The method of claim 1 , wherein the compound is attached to a solid support.
12 . A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases in a mammal comprising the steps of
i) contacting a test compound with a GPR39 polynucleotide, and
ii) detect binding of said test compound to said GPR39 polynucleotide.
13 . The method of claim 12 wherein the nucleic acid molecule is RNA.
14 . The method of claim 12 wherein the contacting step is in or at the surface of a cell.
15 . The method of claim 12 wherein the contacting step is in a cell-free system.
16 . The method of claim 12 wherein polynucleotide is coupled to a detectable label.
17 . The method of claim 12 wherein the test compound is coupled to a detectable label.
18 . A method of diagnosing a disease selected from the group consisting of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases in a mammal comprising the steps of
i) determining the amount of a GPR39 polynucleotide in a sample taken from said mammal, and
ii) determining the amount of GPR39 polynucleotide in healthy and/or diseased mammals.
19 - 20 . (canceled)
21 . A pharmaceutical composition for the treatment of a disease selected from the group consisting of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases in a mammal comprising a therapeutic agent which regulates the activity of a GPR39 polypeptide, wherein said therapeutic agent is
i) a small molecule,
ii) an RNA molecule,
iii) an antisense oligonucleotide,
iv) a polypeptide,
v) an antibody, or
vi) a ribozyme.
22 . A pharmaceutical composition for the treatment of a disease selected from the group consisting of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases in a mammal comprising a GPR39 polynucleotide.
23 . A pharmaceutical composition for the treatment of a disease selected from the group consisting of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases in a mammal comprising a GPR39 polypeptide.
24 - 26 . (canceled)